Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price392.03 USD
Fair value507.66
Ethical score76.6/100
RatingFAIR VALUE
Our investment reviews on this name
2026-08-19Read Accumulation400.82-2.2% to today
2026-08-13Read Distribution400.82-2.2% to today ✓
2026-07-18Read Accumulation464.85-15.7% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Synopsys holds its Distribution at $392.03. Consolidating, no directional conviction, held for 155 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 155 days
Price at the screen
$392.03
Valuation
68.66 trailing · 22.39 forward price to earnings
Values screen
PASS· score 76.6
Beta
1.23
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.64%
Below 33%
Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.15%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
9.20%
Below 49%
Money owed to the company is 9.2% of assets, under the 49% limit.
Pass
Revenue purity
3.94%
Below 5%
Only 3.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 30% discount to our $507.66 fair value, narrow competitive moat, 42.40% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 29.5% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +43% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet code behind every modern chip
Picture the phone in your pocket or the car on the road. None of it works without the complex chips inside, and Synopsys supplies the design software that lets engineers build those chips faster and with fewer errors. Revenue is rising 42 percent, the shares sit 33 percent below our fair value and the business clears our ethical screen without issue.
Forward earnings sit at 22 times, the narrow moat reflects solid but not unassailable technology, and margins remain modest at 9 percent with a 4 percent return on equity. Analysts see further upside to a 575 median target, yet the numbers show a steady compounder rather than a runaway winner.
Semiconductor cycles can still bite and competition from larger players keeps returns modest. The valuation already prices in much of the growth, so any slowdown would close the margin of safety quickly. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SNPS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-26Accumulation$397.92+0.0%Entry 12
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Accumulation$397.92+0.0%Entry 11
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Accumulation$397.92+0.0%Entry 10
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Accumulation$397.92+0.0%Entry 9
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Accumulation$397.92+0.0%Entry 8
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Accumulation$397.92-0.7%Entry 7
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Accumulation$400.82+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
2026-07-18Accumulation$464.85+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
